ATE212237T1 - Verwendung von neuronalen fötalen zellinien für transplantationstherapie - Google Patents

Verwendung von neuronalen fötalen zellinien für transplantationstherapie

Info

Publication number
ATE212237T1
ATE212237T1 AT94912975T AT94912975T ATE212237T1 AT E212237 T1 ATE212237 T1 AT E212237T1 AT 94912975 T AT94912975 T AT 94912975T AT 94912975 T AT94912975 T AT 94912975T AT E212237 T1 ATE212237 T1 AT E212237T1
Authority
AT
Austria
Prior art keywords
cell lines
neuronal
fetal cell
transplantation therapy
svg
Prior art date
Application number
AT94912975T
Other languages
English (en)
Inventor
Eugene O Major
Carlo S Tornatore
Kris Bankiewicz
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE212237T1 publication Critical patent/ATE212237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13041—Tyrosine N-monooxygenase (1.14.13.41)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94912975T 1993-04-13 1994-04-11 Verwendung von neuronalen fötalen zellinien für transplantationstherapie ATE212237T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4652793A 1993-04-13 1993-04-13
PCT/US1994/003938 WO1994023754A1 (en) 1993-04-13 1994-04-11 Use of neuro-derived fetal cell lines for transplantation therapy

Publications (1)

Publication Number Publication Date
ATE212237T1 true ATE212237T1 (de) 2002-02-15

Family

ID=21943916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912975T ATE212237T1 (de) 1993-04-13 1994-04-11 Verwendung von neuronalen fötalen zellinien für transplantationstherapie

Country Status (11)

Country Link
US (3) US5869463A (de)
EP (1) EP0696205B1 (de)
JP (1) JPH08509215A (de)
AT (1) ATE212237T1 (de)
AU (1) AU690548B2 (de)
CA (1) CA2159738A1 (de)
DE (1) DE69429721T2 (de)
DK (1) DK0696205T3 (de)
ES (1) ES2170096T3 (de)
PT (1) PT696205E (de)
WO (1) WO1994023754A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753491A (en) * 1993-04-13 1998-05-19 Us Health Use of neuro-derived fetal cell lines for transplantation therapy
EP0632008B1 (de) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentansäurederivate
FR2714061B1 (fr) * 1993-12-16 1996-03-08 Genset Sa Procédé de préparation de polynucléotides sur support solide et appareil permettant sa mise en Óoeuvre.
US6469157B1 (en) * 1993-12-16 2002-10-22 Proligo Llc Process for preparing polynucleotides on a solid support
US20010049143A1 (en) * 1994-11-08 2001-12-06 Stringer Bradley Michael John Human cell-lines
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
AU742824C (en) * 1995-06-06 2003-03-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of neuro-derived fetal cell lines for transplantation therapy
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
AU7963998A (en) 1997-06-13 1998-12-30 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
WO1998057663A1 (en) 1997-06-17 1998-12-23 University Technology Corporation Neural transplantation for treating neurological disease
AU3888699A (en) 1998-05-07 1999-11-23 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6787356B1 (en) 1998-07-24 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Cell expansion system for use in neural transplantation
RU2155596C2 (ru) * 1998-07-24 2000-09-10 Научный центр акушерства, гинекологии и перинатологии РАМН Способ лечения аутоиммунного мужского бесплодия
EP1109572A4 (de) * 1998-09-03 2004-11-24 Neuronz Ltd Neuroprotektion
GB9907243D0 (en) * 1999-03-29 1999-05-26 Reneuron Ltd Therapy
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US20090047325A1 (en) * 1999-04-30 2009-02-19 Neurotrophincell Pty. Limited Xenotransplant for cns therapy
US20040213768A1 (en) * 1999-04-30 2004-10-28 Elliott Robert Bartlett Preparation for biotransplantation and xenotransplantion and uses thereof
ES2346400T3 (es) * 1999-04-30 2010-10-15 Neurotrophincell Pty Ltd Xenotransplante para la terapia del snc.
US20050169896A1 (en) * 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
US8017112B2 (en) * 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
ES2531592T3 (es) * 1999-05-14 2015-03-17 Henry Ford Health System Trasplante de médula ósea para el tratamiento de la apoplejía
AU780366B2 (en) * 2000-01-20 2005-03-17 Diatranz Otsuka Limited Preparation and xenotransplantation of porcine islets
US7160724B2 (en) * 2000-03-09 2007-01-09 University Of South Florida Human cord blood as a source of neural tissue for repair of the brain and spinal cord
RU2160112C1 (ru) * 2000-04-10 2000-12-10 Сухих Геннадий Тихонович Способ приготовления клеточного трансплантата из фетальных тканей
ATE342723T1 (de) 2000-04-13 2006-11-15 Univ Texas Behandlung von neurodegenerativen gastrointestinalen krankheiten durch implantation von neuralen stammzellen und/oder deren nachkommen in gastrointestinalorgane
RU2200587C2 (ru) * 2000-06-05 2003-03-20 Санкт-Петербургская медицинская академия последипломного образования Способ определения длительности экстракорпоральной детоксикации при опиатном абстинентном синдроме
RU2195941C2 (ru) * 2000-06-19 2003-01-10 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения травматических повреждений спинного мозга
WO2002001242A2 (en) * 2000-06-28 2002-01-03 The Regents Of The University Of Minnesota Imaging methods for visualizing implanted living cells
US20090209831A1 (en) * 2000-06-28 2009-08-20 Nexgen Medical Systems, Incorporated Imaging methods for visualizing implanted living cells
US7831305B2 (en) 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US7112570B2 (en) 2000-08-24 2006-09-26 Neuren Pharmaceuticals, Ltd. GPE analogs
EP1333846B1 (de) * 2000-10-17 2012-04-18 Diabcell Pty Limited Zubereitung und xenotransplantation von langerhans-inseln von schweinen
US7041283B1 (en) * 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants
EP1370134B1 (de) * 2001-03-23 2016-03-23 University Of Ottawa Verfahren und zusammensetzungen zur kryokonservierung von dissoziirten primären tierzellen
EP1401808B1 (de) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe-analoga und peptidomimetika
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US20040092013A1 (en) * 2001-08-14 2004-05-13 Snyder Evan Y. Method of treating alzheimer's disease with cell therapy
ATE535601T1 (de) * 2001-09-28 2011-12-15 Diabcell Pty Ltd Züchtung von fremdtransplantationsmaterial in kultur
NZ515310A (en) * 2001-11-07 2004-08-27 Diabcell Pty Ltd Methods of treatment and delivery modes
ATE492636T1 (de) 2002-10-22 2011-01-15 Eisai R&D Man Co Ltd Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
EP1587545A2 (de) * 2003-01-13 2005-10-26 Mahendra S. Rao Anhaltende expression von molekülkandidaten in proliferierenden stamm- und vorläuferzellen zur abgabe von therapeutischen produkten
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
WO2004113516A1 (en) * 2003-06-24 2004-12-29 Diabcell Pty Limited Porcine islets cultured with porcine sertoli cells for xenotransplantation
US8579908B2 (en) * 2003-09-26 2013-11-12 DePuy Synthes Products, LLC. Device for delivering viscous material
KR101375603B1 (ko) 2004-07-22 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｌｒｐ４／Ｃｏｒｉｎ 도파민 생산 뉴런 전구 세포 마커
DE602005002430T2 (de) 2004-09-30 2008-06-19 Reneuron Ltd., Guildford Zelllinie
US7643864B2 (en) * 2005-02-03 2010-01-05 Case Western Reserve University Adaptive imaging parameters with MRI
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
WO2007021004A1 (ja) 2005-08-18 2007-02-22 Eisai R & D Management Co., Ltd. ドーパミン産生ニューロン増殖前駆細胞マーカーＭｓｘ１／２
CA2627593C (en) 2005-08-18 2012-04-24 Eisai R & D Management Co., Ltd. Dopaminergic neuron proliferative progenitor cell marker nato3
WO2007119759A1 (ja) 2006-04-11 2007-10-25 Eisai R & D Management Co., Ltd. ドーパミン産生ニューロン前駆細胞マーカー１８７ａ５
WO2007133757A2 (en) * 2006-05-15 2007-11-22 Diasys Corporation Reusable slide assembly
US20090090214A1 (en) * 2007-10-04 2009-04-09 Chung Yuan Christian University Method for forming nano-scale metal particles
US9101570B1 (en) 2009-02-13 2015-08-11 Endocellutions, Inc. Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract
JP2013507373A (ja) * 2009-10-08 2013-03-04 ニューロテック ユーエスエー， インコーポレイテッド 被包された細胞ベースの送達系におけるｐｅｄｆの使用
JP6090937B2 (ja) 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707448A (en) * 1984-10-04 1987-11-17 The United States Of America As Represented By The Department Of Health And Human Services Immortal line of human fetal glial cells
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
ATE90724T1 (de) * 1988-04-12 1993-07-15 Massachusetts Inst Technology Verfahren zur manipulation des zelltyps von eukaryonten.
AU4669189A (en) * 1988-11-23 1990-06-12 Baylor College Of Medicine Neural cell transplantation
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system

Also Published As

Publication number Publication date
ES2170096T3 (es) 2002-08-01
PT696205E (pt) 2002-07-31
US20020110546A1 (en) 2002-08-15
DE69429721D1 (de) 2002-03-14
DE69429721T2 (de) 2002-09-05
WO1994023754A1 (en) 1994-10-27
EP0696205B1 (de) 2002-01-23
AU690548B2 (en) 1998-04-30
US5869463A (en) 1999-02-09
US5690927A (en) 1997-11-25
DK0696205T3 (da) 2002-05-13
JPH08509215A (ja) 1996-10-01
CA2159738A1 (en) 1994-10-27
EP0696205A1 (de) 1996-02-14
AU6531294A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
DE69429721D1 (de) Verwendung von neuronalen fötalen zellinien für transplantationstherapie
AU623234B2 (en) An implantable medical instrument with an intensity of stimulation adaptable to the physical activity of the living thing
AU577501B2 (en) Auditory stimulating system
DE69203596D1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69527996D1 (de) Handprogrammiereinrichtung für patienten für einen implantierbaren stimulator für menschliches gewebe
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
AU623241B2 (en) An implantable medical instrument for stimulating a physiological function of a living thing with adjustable intensity of stimulation, and process of adjusting the intensity of stimulation
EP0668771A4 (de) Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen.
GB8921737D0 (en) Device for surgical treatment of ametropia
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE58902777D1 (de) Herrichtung und verwendung eines physiologisch aktiven polypeptids zur aids-therapie.
PL277468A1 (en) Apparatus for surgical treatment of astigmatism
UA30329A (uk) Спосіб лікування хронічних запальних захворювань придатків матки
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
FI885234A0 (fi) Elävään kudokseen implantoitava granuli-implantaatti

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee